Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

J Med Chem 2014 Mar 15;57(5):2047-57. Epub 2014 Jan 15.

Research and Development, AbbVie Inc. , North Chicago, Illinois 60064, United States.

We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics. Compounds with 2S,5S stereochemistry at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared to the 2R,5R analogues. Furthermore, the attachment of substituents at the 4-position of the central N-phenyl group resulted in compounds with improved potency. Substitution with tert-butyl, as in compound 38 (ABT-267), provided compounds with low-picomolar EC50 values and superior pharmacokinetics. It was discovered that compound 38 was a pan-genotypic HCV inhibitor, with an EC50 range of 1.7-19.3 pM against GT1a, -1b, -2a, -2b, -3a, -4a, and -5a and 366 pM against GT6a. Compound 38 decreased HCV RNA up to 3.10 log10 IU/mL during 3-day monotherapy in treatment-naive HCV GT1-infected subjects and is currently in phase 3 clinical trials in combination with an NS3 protease inhibitor with ritonavir (r) (ABT-450/r) and an NS5B non-nucleoside polymerase inhibitor (ABT-333), with and without ribavirin.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm401398xDOI Listing
March 2014
54 Reads
16 Citations
5.450 Impact Factor

Publication Analysis

Top Keywords

hcv ns5a
8
hcv
5
low-picomolar ec50
4
compounds low-picomolar
4
phase clinical
4
abt-267 provided
4
provided compounds
4
ec50 values
4
currently phase
4
discovered compound
4
compound pan-genotypic
4
pharmacokinetics discovered
4
superior pharmacokinetics
4
values superior
4
compound abt-267
4
substitution tert-butyl
4
trials combination
4
n-phenyl group
4
310 log10
4
4-position central
4

Altmetric Statistics

Similar Publications